Average Co-Inventor Count = 7.56
ph-index = 14
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Amylin Pharmaceuticals, Inc. (14 from 164 patents)
2. Astrazeneca Pharmaceuticals LP (10 from 38 patents)
3. Dendreon Corporation (7 from 53 patents)
4. Corvas International, Inc. (6 from 75 patents)
5. Schering Corporation (5 from 1,829 patents)
6. Other (2 from 832,880 patents)
7. Wilex Ag (36 patents)
29 patents:
1. 9593154 - Engineered polypeptides having enhanced duration of action
2. 9453063 - Hybrid polypeptides with selectable properties
3. 9133260 - GIP analog and hybrid polypeptides with selectable properties
4. 8906849 - Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
5. 8895498 - GIP and exendin hybrid polypeptides
6. 8759295 - Peptide-peptidase inhibitor conjugates and methods of using same
7. 8697647 - Hybrid polypeptides with selectable properties
8. 8603969 - Pancreatic polypeptide family motifs and polypeptides comprising the same
9. 8598314 - Peptide-peptidase-inhibitor conjugates and methods of making and using same
10. 8497240 - DPP-IV resistant GIP hybrid polypeptides with selectable properties
11. 8426361 - Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
12. 8404637 - GIP analog and hybrid polypeptides with selectable properties
13. 8263545 - GIP analog and hybrid polypeptides with selectable properties
14. RE43298 - Peptides as NS3-serine protease inhibitors of hepatitis C virus
15. 8076288 - Hybrid polypeptides having glucose lowering activity